Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients

Published:2016-08-05 Issue:44 Volume:7 Page:72311-72321
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Bocchia Monica¹,Galimberti Sara²,Aprile Lara¹,Sicuranza Anna¹,Gozzini Antonella³,Santilli Francesca⁴,Abruzzese Elisabetta⁵,Baratè Claudia²,Scappini Barbara³,Fontanelli Giulia²,Trawinska Monika Malgorzata⁵,Defina Marzia¹,Gozzetti Alessandro¹,Bosi Alberto³,Petrini Mario²,Puccetti Luca¹

Affiliation:

1. Department of Hematology, University of Siena, Azienda Ospedaliera Universitaria Senese, Siena, Italy

2. Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy

3. Functional Unit of Hematology, University of Florence, Florence, Italy

4. Department of Medicine and Aging, University of Chieti, Chieti, Italy

5. Hematology Unit, S. Eugenio Hospital, Tor Vergata University, Rome, Italy

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation;Scientific Reports;2023-07-21

2. Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment;Cancers;2023-06-28

3. Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia;Cancers;2022-09-26

4. Cardioprotection of High-Risk Individuals;Heart Failure Clinics;2022-07

5. Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study);Frontiers in Oncology;2022-02-01